Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
14 09 2022
Historique:
received: 23 12 2021
revised: 06 05 2022
accepted: 12 05 2022
pubmed: 21 5 2022
medline: 17 9 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

Isolated REM sleep behaviour disorder (iRBD) is a synucleinopathy characterized by abnormal behaviours and vocalizations during REM sleep. Most iRBD patients develop dementia with Lewy bodies, Parkinson's disease or multiple system atrophy over time. Patients with iRBD exhibit brain atrophy patterns that are reminiscent of those observed in overt synucleinopathies. However, the mechanisms linking brain atrophy to the underlying alpha-synuclein pathophysiology are poorly understood. Our objective was to investigate how the prion-like and regional vulnerability hypotheses of alpha-synuclein might explain brain atrophy in iRBD. Using a multicentric cohort of 182 polysomnography-confirmed iRBD patients who underwent T1-weighted MRI, we performed vertex-based cortical surface and deformation-based morphometry analyses to quantify brain atrophy in patients (67.8 years, 84% male) and 261 healthy controls (66.2 years, 75%) and investigated the morphological correlates of motor and cognitive functioning in iRBD. Next, we applied the agent-based Susceptible-Infected-Removed model (i.e. a computational model that simulates in silico the spread of pathologic alpha-synuclein based on structural connectivity and gene expression) and tested if it recreated atrophy in iRBD by statistically comparing simulated regional brain atrophy to the atrophy observed in patients. The impact of SNCA and GBA gene expression and brain connectivity was then evaluated by comparing the model fit to the one obtained in null models where either gene expression or connectivity was randomized. The results showed that iRBD patients present with cortical thinning and tissue deformation, which correlated with motor and cognitive functioning. Next, we found that the computational model recreated cortical thinning (r = 0.51, P = 0.0007) and tissue deformation (r = 0.52, P = 0.0005) in patients, and that the connectome's architecture along with SNCA and GBA gene expression contributed to shaping atrophy in iRBD. We further demonstrated that the full agent-based model performed better than network measures or gene expression alone in recreating the atrophy pattern in iRBD. In summary, atrophy in iRBD is extensive, correlates with motor and cognitive function and can be recreated using the dynamics of agent-based modelling, structural connectivity and gene expression. These findings support the concepts that both prion-like spread and regional susceptibility account for the atrophy observed in prodromal synucleinopathies. Therefore, the agent-based Susceptible-Infected-Removed model may be a useful tool for testing hypotheses underlying neurodegenerative diseases and new therapies aimed at slowing or stopping the spread of alpha-synuclein pathology.

Identifiants

pubmed: 35594873
pii: 6589819
doi: 10.1093/brain/awac187
doi:

Substances chimiques

Prions 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3162-3178

Investigateurs

Marie Vidailhet (M)
Jean-Christophe Corvol (JC)
Isabelle Arnulf (I)
Stéphane Lehéricy (S)
Graziella Mangone (G)
Sara Sambin (S)
Jonas Ihle (J)
Caroline Weill (C)
David Grabli (D)
Florence Cormier-Dequaire (F)
Louise Laure Mariani (LL)
Bertrand Degos (B)
Richard Levy (R)
Fanny Pineau (F)
Julie Socha (J)
Eve Benchetrit (E)
Virginie Czernecki (V)
Marie-Alexandrine Glachant (MA)
Sophie Rivaud-Pechoux (S)
Elodie Hainque (E)
Smaranda Leu Semenescu (SL)
Pauline Dodet (P)
Samir Bekadar (S)
Alexis Brice (A)
Suzanne Lesage (S)
Fanny Mochel (F)
Farid Ichou (F)
Vincent Perlbarg (V)
Benoit Colsch (B)
Arthur Tenenhaus (A)
Rahul Gaurav (R)
Nadya Pyatigorskaya (N)
Lydia Yahia-Cherif (L)
Romain Valabrègue (R)
Cécile Galléa (C)
Marie-Odile Habert (MO)
Dijana Petrovska (D)
Laetitia Jeancolas (L)
Vanessa Brochard (V)
Alizé Chalançon (A)
Carole Dongmo-Kenfack (C)
Christelle Laganot (C)
Valentine Maheo (V)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Shady Rahayel (S)

The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.
Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal H4J 1C5, Canada.

Christina Tremblay (C)

The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.

Andrew Vo (A)

The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.

Ying Qiu Zheng (YQ)

Wellcome Centre for Integrative Neuroimaging, Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.

Stéphane Lehéricy (S)

Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris 75013, France.

Isabelle Arnulf (I)

Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris 75013, France.

Marie Vidailhet (M)

Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris 75013, France.

Jean Christophe Corvol (JC)

Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris 75013, France.

Jean François Gagnon (JF)

Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal H4J 1C5, Canada.
Department of Psychology, Université du Québec à Montréal, Montreal H2X 3P2, Canada.
Research Centre, Institut universitaire de gériatrie de Montréal, Montreal H3W 1W5, Canada.

Ronald B Postuma (RB)

Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal H4J 1C5, Canada.
Department of Neurology, Montreal General Hospital, Montreal H3G 1A4, Canada.

Jacques Montplaisir (J)

Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal H4J 1C5, Canada.
Department of Psychiatry, Université de Montréal, Montreal H3T 1J4, Canada.

Simon Lewis (S)

ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Camperdown, NSW 2050, Australia.

Elie Matar (E)

ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Camperdown, NSW 2050, Australia.

Kaylena Ehgoetz Martens (K)

ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Camperdown, NSW 2050, Australia.
Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo N2L 3G1, Canada.

Per Borghammer (P)

Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus DK-8200, Denmark.

Karoline Knudsen (K)

Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus DK-8200, Denmark.

Allan Hansen (A)

Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus DK-8200, Denmark.

Oury Monchi (O)

Research Centre, Institut universitaire de gériatrie de Montréal, Montreal H3W 1W5, Canada.
Departments of Clinical Neurosciences, Radiology, and Hotchkiss Brain Institute, University of Calgary, Calgary T2N 4N1, Canada.

Bratislav Misic (B)

The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.

Alain Dagher (A)

The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH